Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 10 , Pages 1001-1010, October 2010

National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007

  • Jonathan S. Comer, Ph.D.

      Affiliations

    • College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York
    • Corresponding Author InformationCorrespondence to: Jonathan S. Comer, Ph.D., Boston University, Department of Psychology, Center for Anxiety and Related Disorders, 648 Beacon Street 6th Floor, Boston, MA 02446
    • ,
  • Mark Olfson, M.D., M.P.H.

      Affiliations

    • College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York
    • ,
  • Ramin Mojtabai, M.D., Ph.D., M.P.H.

      Affiliations

    • Bloomberg School of Public Health and Johns Hopkins University, Baltimore

Accepted 16 July 2010. published online 02 September 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This work was supported by AHRQ U18 HS016097 and NIH T32 MH016434.

 The authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

 Disclosure: Dr. Olfson, in the past 5 years, has received investigator initiated grants from AstraZeneca, Bristol-Myers Squibb, and Eli Lilly and Co. He has served on the speakers' bureau for Janssen Pharmaceutica, and as a consultant to Pfizer, AstraZeneca, Eli Lilly and Co., and Bristol-Myers Squibb. Dr. Mojtabai has received research funding and consulting fees from Bristol-Myers Squibb. Dr. Comer reports no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(10)00561-7

doi:10.1016/j.jaac.2010.07.007

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 10 , Pages 1001-1010, October 2010

Article Tools

* Image Usage & Resolution